Shareholders Approve Stock Incentive Plan, Authorizing 34% Potential Dilution
INMB sits 19% above its 52-week low of $1.09.
Summary
Inmune Bio shareholders approved an expanded stock incentive plan, potentially diluting existing shareholders by over 34% initially, with further annual dilution authorized through an evergreen provision.
Key Events · Corporate Governance and Compliance · INMB
-
Expanded Stock Incentive Plan Approved
Shareholders approved the Third Amended and Restated 2021 Stock Incentive Plan, increasing the shares reserved for awards from 6.5 million to 9,158,525 shares.
-
Significant Potential Dilution
The 9,158,525 shares authorized for the plan represent a potential dilution of approximately 34.45% based on the 26,585,258 shares outstanding as of the April 20, 2026 record date.
-
Evergreen Provision for Future Dilution
An evergreen provision was approved, allowing for automatic annual increases of up to 10.0% of outstanding shares from 2027 through 2031, adding to long-term dilution potential.
-
Routine Shareholder Matters
Stockholders also re-elected five directors and ratified the appointment of CBIZ CPAs P.C. as the independent auditor for 2026.
Analysis · INMB · Life Sciences
Shareholders approved a significantly expanded stock incentive plan, increasing the total shares reserved for awards to 9.16 million. This represents a potential dilution of approximately 34.45% based on the 26.59 million shares outstanding at the record date. Additionally, an evergreen provision was approved, allowing for annual increases of up to 10% of outstanding shares from 2027 through 2031, which will lead to further substantial dilution over time. While incentive plans are crucial for attracting and retaining talent in a life sciences company, especially following recent positive FDA and clinical trial news, the magnitude of this potential dilution is a significant negative for existing shareholders, particularly given the company's reiterated 'going concern' warning.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INMB was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.6M. The 52-week trading range was $1.09 to $11.64. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.